Pitavastatin (NK-104), a new HMG-CoA reductase inhibitor

Drugs of Today

Volumn 37, Issue 9, 2001, Pages 587-594

  Isley, W L ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; CYTOCHROME P450 3A4; DIAZEPAM; DIGITOXIN; FIBRIC ACID DERIVATIVE; FUROSEMIDE; GEMFIBROZIL; GLIBENCLAMIDE; IBUPROFEN; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; NITRENDIPINE; PHENYLBUTAZONE; PHENYTOIN; PITAVASTATIN; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; TOLBUTAMIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; WARFARIN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; NONHUMAN; REVIEW; SIDE EFFECT;

EID: 0035204867     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2001.37.9.844218     Document Type: Review

References (39)

1. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study
2. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men
3. Pathobiology of human familial hypercholesterolaemia and a related animal model, the Watanabe heritable hyperlipidaemic rabbit
4. The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease
5. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
8. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators
9. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
10. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
11. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
12. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension
13. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia
14. Treatment of hyperlipidemia with combined niacin-statin regimens
15. Baycol withdrawn from market
16. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
17. Clinical effect of NK-104 (nisvastatin) on hyperlipidemia - Double-blind comparative dose-finding study in three parallel groups
18. NK-104, a potent new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, enhances posttranslational catabolism of apolipoprotein B-100 and inhibits secretion of apolipoprotein B-100 and triacylglycerols from HepG2 cells
19. NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells
20. Effect of NK-104, an HMG-CoA reductase inhibitor on lipid metabolism in HepG2 cells
21. 14C-NK-104 in rats
22. Identification of metabolites of NK-104, and HMG-CoA reductase inhibitor, in rat, rabbit and dog bile
23. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): Absorption, distribution, metabolism and excretion in rats
24. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4): Interspecies variation in laboratory animals and humans
25. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): In vitro metabolism and plasma protein binding in animals and humans
26. Lipid-lowering and antiatherosclerotic effect of NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, and Watanabe heritable hyperlipidemic rabbits
27. Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pig
28. Mutagenicity studies of (+)-monocalcium bis[(3R, 5S, 3E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3, 5-dihydroxy-6-heptenoate] (NK-104)
29. General pharmacological study of an antihyperlipidemic agent, NK-104
30. Antigenicity studies of (+)-monocalcium bis [3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3, 5-dihydroxy-6-heptenoate] (NK-104) in guinea pigs
31. Single dose toxicity studies of (+)-monocalcium bis[(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3, 5-dihydroxy-6-heptenoate] (NK-104) in rats and dogs
32. A 3-month oral toxicity study of (+)-monocalcium bis[(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3, 5-dihydroxy-6-heptenoate] (NK-104) in dogs followed by a 7-week recovery test
33. A 12-month oral toxicity study of (+)-monocalcium bis[(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3, 5-dihydroxy-6-heptenoate](NK- 104) in dogs followed by a 2-month recovery test
34. Reproductive and developmental toxicity studies of (+)-monocalcium bis[(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3, 5-dihydroxy-6-heptenoate] (NK-104): 1. Fertility study in rats by oral administration
35. Reproductive and developmental toxicity studies of (+)-monocalcium bis [(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3, 5-dihydroxy-6-heptenoate] (MK 104): 2. Teratogenicity study in rats by oral administration
36. Reproductive and developmental toxicity study of (+)-monocalcium bis[(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3, 5-dihydroxy-6-heptenoate] (NK-104): 3. Teratogenicity study in rabbits by oral administration
37. Reproductive and developmental toxicity studies of (+)-monocalcium bis[(3R, 5S, 6R)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3, 5-dihydroxy-6-heptenoate] (NK-104): 4. Perinatal and postnatal study in rats by oral administration
38. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (3): Foeto-placental transfer and mammary excretion after oral administration in rats
39. Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia